🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

From Siteman Cancer Center PTCL/CTCL expert @NehaMehtaShahMD and former WashU Medicine Hematology-Oncology Fellowship Lauren Shea. 🤩🤩🤩

Presented my fellowship LOI project, CNS PHLAT, an IIT feasibility study to prevent CNS relapse in high risk DLBCL patients using thiotepa based auto transplant! Open to enrollment at WashU as of 1/16/25 WashU Medicine Division of Oncology Siteman Cancer Center WashU Medicine Hematology-Oncology Fellowship

So proud of all of the hard work our fellows do! All of our fellows write and run a prospective trial starting from their first year of fellowship. Check out their projects below!

On #WorldCancerDay, we offer hope and strength to everyone affected by cancer. By raising awareness, promoting early detection, and supporting vital research, we can create a brighter future. Join us in the fight. 💜#CancerAwareness #TogetherWeCan WashU Medicine Division of Oncology Siteman Cancer Center

The fellows had a great time learning about various career paths - academia, community, industry, VA, and more! Thanks, Dr. Sanfilippo and the Wellness for setting this up!

Check out our all-star second year fellow Ling at #Tandem25! WashU Medicine Division of Hematology

Congratulations to one our outstanding WashU Medicine Hematology-Oncology Fellowship Emily Podany @podanymd on the publication of her article "Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer" in JAMA Network Open WashU Medicine Division of Oncology jamanetwork.com/journals/jaman…

Read this important study on racial disparities in metastatic breast cancer in JAMA Network Open by 3rd-year fellow Emily Podany. #bcsm #MedEd WashU Medicine Division of Oncology WashU Medicine Department of Medicine Siteman Cancer Center Barnes-Jewish WashU Medicine Future Workforce in Med (FWIM) WashU Medicine Abby Spencer, MD, MS, FACP sites.wustl.edu/hemeoncfellows…

In a study published in NEJM involving more than 1700 patients with cancer-related VTE, reduced-dose apixaban (2.5 mg twice daily) resulted in similar 12-month VTE recurrence rates compared with full-dose (5 mg twice daily) apixaban (2.1 versus 2.8 per cent). However, fewer

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by David Russler-Germain, MD/PhD at #18icml International Conference on Malignant Lymphoma, now available online in Cancer Cell. #lmsm WashU Medicine MD Anderson Cancer Center. cell.com/cancer-cell/fu…

Congrats to incoming fellow Kelsey Bria who presented her work at ISTH 2025!